Stock KTTA PASITHEA THERAPEUTICS CORP.
Add to a list
To use this feature you must be a member
Log inSign up

All News Pasithea Therapeutics Corp.

Equities

KTTA

US70261F2020

Market Closed - Nasdaq
Other stock markets
 02:00:01 27/06/2024 am IST 		5-day change 1st Jan Change
5.265 USD -0.65% Intraday chart for Pasithea Therapeutics Corp. +2.44% -28.85%
13/06 Pasithea Therapeutics Corp. Announces Completion of Enrollment and Initial Dosing of Cohort 2 Following Positive Safety Review Committee Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial CI
14/05 Pasithea Therapeutics Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial
AQ
Pasithea Therapeutics Corp. Announces Completion of Enrollment and Initial Dosing of Cohort 2 Following Positive Safety Review Committee Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial
CI
Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting
AQ
Pasithea Therapeutics : Shareholder Meeting - Form 8-K
PU
Pasithea Therapeutics Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting
AQ
Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers
AQ
Pasithea Therapeutics Corp. Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated Cancers
CI
Pasithea Therapeutics Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004
AQ
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for Its Phase 1 Trial of Pas-004
CI
Top Premarket Decliners
MT
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004, Establishes Strengthened Intellectual Property Position
AQ
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position
AQ
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position
CI
Pasithea Therapeutics Shares Rise on FDA Clearance to Evaluate PAS-004 in Advanced Cancer Patients
MT
Pasithea Therapeutics Gets FDA Acceptance for PAS-004 IND Application
DJ
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
AQ
Pasithea Therapeutics Corp. Announces FDA Acceptance of Ind Application to Evaluate Pas-004 in Advanced Cancer Patients
CI
Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KTTA Stock
  4. News Pasithea Therapeutics Corp.